In vitro tests aiding ecological risk assessment of ciprofloxacin, tamoxifen and cyclophosphamide in range of concentrations released in hospital wastewater and surface water

Environment International

Volumn 63, Issue , 2014, Pages 191-200

  Mater, N ^a   Geret, F ^c   Castillo, L ^d   Faucet Marquis, V ^a   Albasi, C ^a,b   Pfohl Leszkowicz, A ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c Laboratoire Geode   (France)

^d Veolia Environnement Recherche et Innovation   (France)

Author keywords

Bioassays; Ciprofloxacin; Cyclophosphamide; Hormesis; Tamoxifen; Wastewater

Indexed keywords

ANTIBIOTICS; BACTERIA; BIOASSAY; CELLS; DNA; DRUG DOSAGE; EFFLUENT TREATMENT; EFFLUENTS; HOSPITALS; MIXTURES; RISK ASSESSMENT; WASTEWATER;

ANTICANCER TREATMENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; ECOLOGICAL RISK ASSESSMENT; ECOTOXICOLOGICAL EFFECTS; ECOTOXICOLOGICAL TESTS; HORMESIS; TAMOXIFEN;

CYTOLOGY;

CIPROFLOXACIN; CYCLOPHOSPHAMIDE; SURFACE WATER; TAMOXIFEN;

BIOASSAY; BIOMARKER; CANCER; CONCENTRATION (COMPOSITION); DRUG; ECOTOXICOLOGY; EFFLUENT; GENOTOXICITY; RISK ASSESSMENT; WASTEWATER;

ALIIVIBRIO FISCHERI; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL VIABILITY; COMET ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG EXPOSURE; ECOTOXICOLOGY; GENOTOXICITY; HOSPITAL WASTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RISK ASSESSMENT; SELENASTRUM CAPRICORNUTUM; WASTE WATER;

ALGAE;

BIOASSAYS; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; HORMESIS; TAMOXIFEN; WASTEWATER;

CELL PROLIFERATION; CELL SURVIVAL; CIPROFLOXACIN; COMET ASSAY; CYCLOPHOSPHAMIDE; DNA DAMAGE; ECOLOGICAL PARAMETER MONITORING; ECOSYSTEM; HEP G2 CELLS; HEPATOCYTES; HUMANS; MEDICAL WASTE; RISK ASSESSMENT; TAMOXIFEN; WASTE WATER;

EID: 84889587777     PISSN: 01604120     EISSN: 18736750     Source Type: Journal    
DOI: 10.1016/j.envint.2013.11.011     Document Type: Article

References (77)

1. Altenburger R., Nendza M., Schüürmann G. Mixture toxicity and its modeling by quantitative structure-activity relationships. Environ Toxicol Chem 2003, 22:1900-1915.
2. Barltrop J.A., Owen T.C., Cory A.H., Cory J.G. 5-(3-Carboxymethoxyphenyl)-2-(4,5-dimethylthiazolyl)-3-(4-sulfophenyl)tetrazolium, inner salt (MTS) and related analogs of 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) reducing to purple water-soluble formazans As cell-viability indicators. Bioorg Med Chem Lett 1991, 1:611-614.
3. Baumgartner A., Cemeli E., Anderson D. The comet assay in male reproductive toxicology. Cell Biol Toxicol 2007, 25:81-98.
4. Besse J.-P., Latour J.-F., Garric J. Anticancer drugs in surface waters: what can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs?. Environ Int 2012, 39:73-86.
5. Bound J.P., Voulvoulis N. Predicted and measured concentrations for selected pharmaceuticals in UK rivers: implications for risk assessment. Water Res 2006, 40:2885-2892.
6. Bouraoui S., Brahem A., Tabka F., Mrizek N., Saad A., Elghezal H. Assessment of chromosomal aberrations, micronuclei and proliferation rate index in peripheral lymphocytes from Tunisian nurses handling cytotoxic drugs. Environ Toxicol Pharmacol 2011, 31:250-257.
7. Breithofer A., Graumann K., Scicchitano M.S., Karathanasis S.K., Butt T.R., Jungbauer A. Regulation of human estrogen receptor by phytoestrogens in yeast and human cells. J Steroid Biochem Mol Biol 1998, 67:421-429.
8. Buerge I.J., Buser H.-R., Poiger T., Müller M.D. Occurrence and fate of the cytostatic drugs cyclophosphamide and ifosfamide in wastewater and surface waters. Environ Sci Technol 2006, 40:7242-7250.
9. Burgaz S., Karahalil B., Bayrak P., Taşkin L., Yavuzaslan F., Bökesoy I., et al. Urinary cyclophosphamide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics. Mutat Res 1999, 439:97-104.
10. Burgaz S., Karahalil B., Canhi Z., Terzioglu F., Ançel G., Anzion R.B.M., et al. Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations. Hum Exp Toxicol 2002, 21:129-135.
11. Calabrese E.J. Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses. Crit Rev Toxicol 2005, 35:463-582.
12. Calabrese E.J. Hormesis once marginalized, evidence now supports hormesis as the most fundamental dose response. Hormesis 2013, Springer science+Business Media. 10.1007/978-1-60761-495-1_2. M.P. Mattson, E.J. Calabrese (Eds.).
13. Carabineiro S.A.C., Thavorn-Amornsri T., Pereira M.F.R., Figueiredo J.L. Adsorption of ciprofloxacin on surface-modified carbon materials. Water Res 2011, 45:4583-4591.
14. Catastini C., Mullot J.-U., Boukari S., Mazellier P., Levi Y., Cervantes P., et al. Identification de molécules anticancéreuses dans les effluents hospitaliers. Eur J Water Qual 2010, 39:171-180.
15. Chou T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681.
16. Chou T.-C. The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. Am J Cancer Res 2011, 1:925.
17. Coe T.S., Hamilton P.B., Hodgson D., Paull G.C., Stevens J.R., Sumner K., et al. An environmental estrogen alters reproductive hierarchies, disrupting sexual selection in group-spawning fish. Environ Sci Technol 2008, 42:5020-5025.
18. Coezy E., Borgna J.-L., Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982, 42:317-323.
19. Costantini D., Metcalfe N.B., Monaghan P. Ecological processes in a hormetic framework. Ecol Lett 2010, 13:1435-1447.
20. Crane M., Watts C., Boucard T. Chronic aquatic environmental risks from exposure to human pharmaceuticals. Sci Total Environ 2006, 367:23-41.
21. Darvari R., Boroujerdi M. Concentration dependency of modulatory effect of amlodipine on P-glycoprotein efflux activity of doxorubicin-a comparison with tamoxifen. J Pharm Pharmacol 2004, 56:985-991.
22. Desai P.B., Nallani S.C., Sane R.S., Moore L.B., Goodwin B.J., Buckley D.J., et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos 2002, 30:608-612.
23. Desta Z., Ward B.A., Soukhova N.V., Flockhart D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004, 310:1062-1075.
24. EFSA Minimum criteria for the acceptance of in vivo alkaline comet assay reports. Efsa J 2012, 10(11):2977-2989.
25. Eguchi K., Nagase H., Ozawa M., Endoh Y.S., Goto K., Hirata K., et al. Evaluation of antimicrobial agents for veterinary use in the ecotoxicity test using microalgae. Chemosphere 2004, 57:1733-1738.
26. Emmanuel E., Perrodin Y., Keck G., Blanchard J.M., Vermande P. Ecotoxicological risk assessment of hospital wastewater: a proposed framework for raw effluents discharging into urban sewer network. J Hazard Mater 2005, 117:1-11.
27. Frenzilli G., Nigro M., Lyons B. The comet assay for the evaluation of genotoxic impact in aquatic environments. Mutat Res Rev Mutat Res 2009, 681:80-92.
28. Fucic A., Jazbec A., Mijic A., Seso-Simic D., Tomek R. Cytogenetic consequences after occupational exposure to antineoplastic drugs. Mutat Res 1998, 416:59-66.
29. Gartiser S., Brinker L., Erbe T., Kümmerer K., Willmund R. Contamination of hospital wastewater with hazardous compounds as define § 7a. Acta Hydrochim Hydrobiol 1996, 24:90-97.
30. Halling-Sørensen B., Nors Nielsen S., Lanzky P.F., Ingerslev F., Holten Lützhøft H.C., Jørgensen S.E. Occurrence, fate and effects of pharmaceutical substances in the environment-a review. Chemosphere 1998, 36:357-393.
31. Hartmann A., Alder A.C., Koller T., Widmer R.M. Identification of fluoroquinolone antibiotics as the main source of umuC genotoxicity in native hospital wastewater. Environ Toxicol Chem 1998, 17:377-382.
32. Hernando M.D., Heath E., Petrovic M., Barceló D. Trace-level determination of pharmaceutical residues by LC-MS/MS in natural and treated waters. A pilot-survey study. Anal Bioanal Chem 2006, 385:985-991.
33. Hoffmann G.R. A perspective on the scientific, philosophical, and policy dimensions of hormesis. Dose-response 2009, 7:1-51.
34. Huang Z., Roy P., Waxman D.J. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000, 59:961-972.
35. Jean J., Perrodin Y., Pivot C., Trepo D., Perraud M., Droguet J., et al. Identification and prioritization of bioaccumulable pharmaceutical substances discharged in hospital effluents. J Environ Manage 2012, 103:113-121.
36. Johnson A.C., Jürgens M.D., Williams R.J., Kümmerer K., Kortenkamp A., Sumpter J.P. Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study. J Hydrol 2008, 348:167-175.
37. Jonker M.J., Piskiewicz A.M., Castellà N.I.I., Kammenga J.E. Toxicity of binary mixtures of cadmium-copper and carbendazim-copper to the nematode Caenorhabditis elegans. Environ Toxicol Chem 2004, 23:1529-1537.
38. Jonker M.J., Svendsen C., Bedaux J.J.M., Bongers M., Kammenga J.E. Significance testing for synergistic/antagonistic, dose level-dependent, or dose ration-dependent effects in mixture dose-response analysis. Environ Toxicol Chem 2005, 24(10):2701-2713.
39. Jordan V.C., Koerner S. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 1975, 11:205-206.
40. Kanuri M., Minko I.G., Nechev L.V., Harris T.M., Harris C.M., Lloyd R.S. Error prone translesion synthesis past gamma-hydroxypropano deoxyguanosine, the primary acrolein-derived adduct in mammalian cells. J Biol Chem 2002, 277:18257-18265.
41. Karthikeyan K.G., Meyer M.T. Occurrence of antibiotics in wastewater treatment facilities in Wisconsin, USA. Sci Total Environ 2006, 361:196-207.
42. Kerbusch T., de Kraker J., Keizer H.J., van Putten J.W., Groen H.J., Jansen R.L., et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 2001, 40:41-62.
43. Kolpin D.W., Furlong E.T., Meyer M.T., Thurman E.M., Zaugg S.D., Barber L.B., et al. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ Sci Technol 2002, 36:1202-1211.
44. Kuemmerer K., Steger-Hartmann T., Meyer M. Biodegradability of the anti-tumour agent ifosfamide and its occurrence in hospital effluents and communal sewage. Water Res 1997, 31:2705-2710.
45. Lindberg R., Jarnheimer P.-A., Olsen B., Johansson M., Tysklind M. Determination of antibiotic substances in hospital sewage water using solid phase extraction and liquid chromatography/mass spectrometry and group analogue internal standards. Chemosphere 2004, 57:1479-1488.
46. Lindberg R.H., Wennberg P., Johansson M.I., Tysklind M., Andersson B.A.V. Screening of human antibiotic substances and determination of weekly mass flows in five sewage treatment plants in Sweden. Environ Sci Technol 2005, 39:3421-3429.
47. Liwei S., Jinmiao Z., Philip A.S., Zijian W. Tamoxifen effects on the early life stages and reproduction of Japanese medaka (Oryzias latipes). Environ Toxicol Pharmacol 2007, 24:23-29.
48. Lu S.C., Huang H.Y. Comparison of sulfur amino acid utilization for GSH synthesis between HepG2 cells and cultured rat hepatocytes. Biochem Pharmacol 1994, 47:859-869.
49. Ma J., Lu N., Qin W., Xu R., Wang Y., Chen X. Differential responses of eight cyanobacterial and green algal species, to carbamate insecticides. Ecotoxicol Environ Saf 2006, 63:268-274.
50. Martins A.F., Vasconcelos T.G., Henriques D.M., Carla da S Frank, König A., Kümmerer K. Concentration of ciprofloxacin in Brazilian hospital effluent and preliminary risk assessment: a case study. CLEAN - Soil Air Water 2008, 36:264-269.
51. McLellan R.A., Drobitch R.K., Monshouwer M., Renton K.W. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 1996, 24:1134-1138.
52. Mersch-Sundermann V., Knasmüller S., Wu X.-J., Darroudi F., Kassie F. Use of a human-derived liver cell line for the detection of cytoprotective, antigenotoxic and cogenotoxic agents. Toxicology 2004, 198:329-340.
53. Miao X.-S., Bishay F., Chen M., Metcalfe C.D. Occurrence of antimicrobials in the final effluents of wastewater treatment plants in Canada. Environ Sci Technol 2004, 38:3533-3541.
54. Negreira N., López de Alda M., Barceló D. On-line solid phase extraction-liquid chromatography-tandem mass spectrometry for the determination of 17 cytostatics and metabolites in waste, surface and ground water samples. J Chromatogr A 2013, 1280:64-74.
55. Negreira N., Mastroianni N., López de Alda M., Barceló D. Multianalyte determination of 24 cytostatics and metabolites by liquid chromatography-electrospray-tandem mass spectrometry and study of their stability and optimum storage conditions in aqueous solution. Talanta 2013, 116:290-299.
56. Orias F., Perrodin Y. Characterisation of the ecotoxicity of hospital effluents: a review. Sci Total Environ 2013, 454-455:250-276.
57. PhACT Database Pharmaceutical Research and Manufacturers of America (PhRMA) 2006.
58. Randall W.A., Price C.W., Welch H. Demonstration of hormesis (increase in fatality rate) by penicillin*. Am J Public Health Nations Health 1947, 37:421-425.
59. Roberts P.H., Thomas K.V. The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. Sci Total Environ 2006, 356:143-153.
60. Rowney N.C., Johnson A.C., Williams R.J. Cytotoxic drugs in drinking water: a prediction and risk assessment exercise for the Thames catchment in the United kingdom. Environ Toxicol Chem 2009, 28:2733-2743.
61. Sane R.S., Buckley D.J., Buckley A.R., Nallani S.C., Desai P.B. Role of human pregnane X receptor in tamoxifen- and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells. Drug Metab Dispos 2008, 36:946-954.
62. Santos L.H.L.M.L., Gros M., Rodriguez-Mozaz S., Delarue-Matos C., Penas A., Barcelo D., et al. Contribution of hospital effluents to the load of pharmaceuticals in urban wastewaters: identification of ecologically relevant pharmaceuticals. Sci Total Environ 2013, 461-462:302-316.
63. Scripture C.D., Sparreboom A., Figg W.D. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 2005, 6:780-789.
64. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988, 175:184-191.
65. Sridar C., Kent U.M., Notley L.M., Gillam E.M., Hollenberg P.F. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther 2002, 301:945-952.
66. Thomas K.V., Hilton M.J. The occurrence of selected human pharmaceutical compounds in UK estuaries. Mar Pollut Bull 2004, 49:436-444.
67. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000, 35:206-221.
68. Tjan-Heijnen V.C., Postmus P.E., Ardizzoni A., Manegold C.H., Burghouts J., van Meerbeeck J., et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 2001, 12:1359-1368.
69. Vandenberg L.N., Colborn T., Hayes T.B., Heindel J.J., Jacobs D.R., Lee D.-H., et al. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev 2012, 33:378-455.
70. Verlicchi P., Al Aukidy M., Galletti A., Petrovic M., Barceló D. Hospital effluent: investigation of the concentrations and distribution of pharmaceuticals and environmental risk assessment. Sci Total Environ 2012, 430:109-118.
71. Wenzel S.D.A., Schäfers C., Vollmer G., Michna H., Diel P., Köln D.S., et al. Research efforts towards the development and validation of a test method for the identification of endocrine disrupting chemicals. Contract 2001, 6:000015.
72. Xie H.-J., Griskevicius L., Broberg U., Lundgren S., Carlens S., Meurling L., et al. Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome P450 genes by ciprofloxacin. Bone Marrow Transplant 2003, 31:197-203.
73. Yusuf A.T., Vian L., Sabatier R., Cano J.P. In vitro detection of indirect-acting genotoxins in the comet assay using HeP G2 cells. Mutat Res 2000, 468:227-234.
74. Zegura B., Heath E., Cernosa A., Filipic M. Combination of in vitro bioassays for the determination of cytotoxic and genotoxic potential of wastewater, surface water and drinking water samples. Chemosphere 2009, 75:1453-1460.
75. Zorita S., Mårtensson L., Mathiasson L. Occurrence and removal of pharmaceuticals in a municipal sewage treatment system in the south of Sweden. Sci Total Environ 2009, 407:2760-2770.
76. Zounkova R., Kovalova L., Blaha L., Dott W. Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites. Chemosphere 2010, 81:253-260.
77. Zuccato E., Castiglioni S., Fanelli R. Identification of the pharmaceuticals for human use contaminating the Italian aquatic environment. J Hazard Mater 2005, 122:205-209.